Emmanuel Ligner

President and CEO, Cytiva
Danaher Group Executive

Emmanuel Ligner lives by the words “Make it personal, make it better.” He encourages diversity of thought among his leadership team to drive the best outcomes in the service of patients.

Emmanuel’s deep roots in biopharma, leadership and engineering began in Tokyo, Japan, in 1996 with Otsuka Pharmaceutical International Ltd. He stepped into various roles, and in 1999 became Marketing Director, Diagnostic Division and later Commercial Director, Diabetes Care Division for Abbott Diagnostics. Later he moved to the UK to become Vice President, Sales and Marketing Europe, for Whatman International.

He’s been the President of Cytiva since July 2017, when it was known as GE Healthcare Life Sciences. In 2021 he was appointed Group Executive of the Danaher Biotechnology Group, consisting of Cytiva and Pall Life Sciences, which united as one company in May 2023.

Emmanuel joined GE Healthcare in April 2008, following its acquisition of Whatman International Plc. His career has spanned many continents and business areas that experienced massive growth under his leadership - from heading up the North America BioProcess business to the Commercial part of Life Sciences across Europe, the Middle East and Africa, and holding the position of General Manager of Core Imaging (now Pharmaceutical Diagnostics) until he was named President.

Emmanuel is a French citizen and earned his Master’s Degree in Commercial Engineering at L’Université Savoie, France.